Search
Menu
Home
HTB
2000
July
HTB
July 2000
Contents
Conference reports
4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain
Tenofovir (PMPA), defining cross-resistance profiles
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV
Hydroxyurea is active in vitro against multidrug-resistant HIV
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
Ritonavir/saquinavir combination: effect of ritonavir dosage
What is the significance of blips in viral load?
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
A prospective study of strategic treatment interruptions in patients with chronic HIV-infection
Added value of hydroxyurea or IL-2 to STIs remains uncertain
Continued benefits from protease inhibitor based therapy despite virological failure
Do resistance mutations disappear off therapy?
Selection of PI mutations during slow decay of VL and resistance after PI failure
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
Nevirapine vs efavirenz: the SENC trial
A warning on simplification strategies: not suitable for all
Antiretrovirals
Nevirapine daily exposure for daily 400 mg dose compared to 200 mg twice-daily
Paediatric care
Gastrostomy tube (G-tube) insertion for improvement of adherence to HAART in pediatric patients with HIV
Side effects
Study of amino acid methionine for treatment of myelopathy
3rd report of patient whose NRTI-associated lactic acidosis responded to riboflavin (vitamin B2)
Basic science and immunology
Accelerated replicative senescence of the peripheral immune system induced by HIV infection
Vaccines and microbicides
NIH suspends enrolment in Remune study
Drug resistance
Immune response may persist after emergence of protease inhibitor-resistant HIV
Other news
Hit HIV-1 hard, but only when necessary
On the web
Prophylaxis and treatment of malaria in the presence of HIV protease inhibitor therapy
The 4th International AIDS Malignancy Conference
PDFs
Volume 1 Number 4 July 2000 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage